Cardiff Oncology, Inc. announced on November 19, 2024, that the United States Patent and Trademark Office (USPTO) has issued U.S. patent No. 12,144,813. This new patent specifically covers the method of using onvansertib in combination with standard of care for the treatment of KRAS mutated metastatic colorectal cancer (mCRC). The patent is expected to provide protection until at least 2043.
This intellectual property expansion is a strategic move that solidifies the company's position in the mCRC treatment landscape. The patent ensures market exclusivity for onvansertib in a critical patient population, which is vital for future commercialization efforts. Securing such long-term patent protection enhances the value proposition of onvansertib.
The patent's claims are focused on the KRAS mutated mCRC setting, an area of significant unmet medical need. This development supports Cardiff Oncology's broader strategy to leverage PLK1 inhibition to develop novel therapies across a range of cancers, with mCRC being a primary focus.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.